DiscoveRx Expands into Immunology Market with Launch of New Human Primary Cell-Based T Cell Autoimmune Panel

Release date: 10/22/2013

Fremont, California, October 22nd, 2013 - DiscoveRx Corporation, through its BioSeek® division, today announces the release of an industry-first, primary human cell-based assay panel for T Cell and Autoimmune research in drug discovery.  Comprised of co-cultures of immune and adherent human primary cell types, these cell-based assay systems model the adaptive immune cell microenvironment involving T and B cell responses.  The T Cell Autoimmune Panel represents a focused suite of T cell-based systems broadly covering immune biology that will enable researchers to evaluate and predict compound impact on immune processes, guide disease indication selection, identify potential biomarkers, and differentiate against existing standards-of-care.

“By developing human primary model systems that model the body’s own defense mechanisms, the T Cell Autoimmune Panel provides a powerful tool to enhance the understanding of compound effects and use the resulting predictive and physiologically relevant information to support the development of targeted therapeutics, such as immuno- and oncology focused compounds” said Ellen Berg, Ph.D., Scientific Director and General Manager of BioSeek.  “In recapitulating the complex interactions associated with autoimmune biology such as T and B cell activation, immune modulation, immunosuppression, T cell skewing, inflammation and tissue remodeling, this panel provides an effective and efficient in vitro model for interrogating in vivo drug activities to predict potential outcomes with respect to drug efficacy and safety.”  For pricing inquiries, request for collaboration and project proposals, please send an email to busdev@bioseekinc.com.

About BioMAP Systems

BioMAP® Systems incorporate predictive primary human cell-based disease models that generate uniquely informative activity profiles of each potential drug, assisting in the selection and development of new drug candidates. For more information on BioMAP drug discovery services, visit www.biomapsystems.com

About DiscoveRx Corporation
Founded in 2000, DiscoveRx is a privately held, venture-backed company headquartered in Fremont, California, with additional offices in San Diego, CA., San Francisco, CA.  and Birmingham, England. DiscoveRx is a leading provider of next generation proprietary platforms for both target-based and phenotypic based drug discovery.  The company holds extensive intellectual property for its core technology platforms 1) PathHunter®, HitHunter® and  InCELL Hunter™: β-galactosidase based enzyme fragment complementation, 2) KINOMEscan® : in vitro binding assay platform and 3) BioMAP: A three part drug discovery solution consisting of BioMAP system, proprietary database, and predictive analytics tools. Utilizing these proprietary platforms, DiscoveRx has developed and commercialized industry leading panels of over 1000 target based and primary cell based assay solutions for Oncology, Metabolic Disease, Inflammation, CNS and Cardiovascular drug discovery research.  Many of DiscoveRx’s innovative solutions have been widely adopted in pharmaceutical, biotechnology and academic laboratories worldwide. For more information, visit www.discoverx.com.


Media Contact
DiscoveRx Corporation
Sailaja Kuchibhatla
Sr. VP Business Development
42501 Albrae Street, Fremont, CA 94538
tel | 510.979.1415 x104
skuchibhatla@discoverx.com
www.discoverx.com